PRO-VERAPAMIL SR TABLET (EXTENDED-RELEASE)

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VERAPAMIL HYDROCHLORIDE

Saadav alates:

PRO DOC LIMITEE

ATC kood:

C08DA01

INN (Rahvusvaheline Nimetus):

VERAPAMIL

Annus:

240MG

Ravimvorm:

TABLET (EXTENDED-RELEASE)

Koostis:

VERAPAMIL HYDROCHLORIDE 240MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113846003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2018-07-26

Toote omadused

_ _
_PRO-VERAPAMIL SR Product Monograph _
_Page 1 of 40_
PRODUCT MONOGRAPH
PR
PRO-VERAPAMIL SR
Verapamil hydrochloride Sustained-Release Tablets, USP
240 mg
Antihypertensive Agent
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Revision:
January 17, 2017
Submission Control No.: 201003
_ _
_PRO-VERAPAMIL SR Product Monograph _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
................................................................................27
PHARMACEUTICAL INFORMATION
..........................................................................27
CLINICAL TRIALS
..........................................................................................................28
DETAILED PHARMA